An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Development of new treatments for diseases such as multiple myeloma is a focus for research.
The research being conducted is on treatment called Anti-KIR (1-7F9), which activates the
body's own cells to kill tumor cells. This is different from many other treatments where
chemicals are given to kill tumor cells. The purpose of the study is to determine a safe dose
of Anti-KIR (1-7F9) to administer in humans and to gain information about its effectiveness
in the treatment of multiple myeloma.